Showing 2644 results
- Media Release /New long-term data from EXPAND show patients with SPMS continuously treated with Mayzent® (siponimod) experienced lower risk of disability progression and cognitive decline than patients who delayed…
- Media Release /Novartis has reached an agreement with the US Food and Drug Administration (FDA) to proceed with a Phase III clinical trial of hydroxychloroquine in hospitalized patients with COVID-19 disease Trial…
- Media Release /Novartis will present 34 abstracts from leading MS portfolio, including the highly anticipated results from the Phase III trial of investigational B-cell therapy ofatumumab (OMB157), data for Mayzent…
- Media Release /The 5-year open-label treatment period (OLTP) examines sustained efficacy and long-term safety of Aimovig® (erenumab) in patients with episodic migraine, starting on 70mg and switched after two years…
- Media Release /Currently, there are no targeted therapies approved to treat MET exon14 skipping-mutated non-small cell lung cancer (NSCLC), a particularly aggressive form of the diseaseBreakthrough Therapy…
- Story /
- Story /
- Story /
- Media Release /Results from the Migraine Care support program show that employer-initiated educational and counselling support cut migraine-related disability by more than half after 6 months[1] …
- Media Release /Worldwide agreement with Polpharma Biologics gives Sandoz commercialization rights to proposed biosimilar natalizumab for relapsing-remitting multiple sclerosis (RRMS) RRMS affects ~85% of MS…
Pagination
- ‹ Previous page
- 1
- …
- 222
- 223
- 224
- 225
- 226
- 227
- 228
- …
- 265
- › Next page